Stockreport

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025Conference call to be held today at 10:00 am Eastern TimeCAESAREA, Israel, [Read more]